Lonza Partners with Vineti Across its Cell and Gene Therapy Manufacturing Network to Optimize 'Vein-to-Vein' Delivery Service

July 30,2019
  • Vineti and Lonza as preferred partners, respectively for patient tissue tracking and contract development and manufacturing services in cell and gene therapy
     
  • Unique partnership comprises fully integrated offering including logistics, scheduling, distribution, Chain of Condition, Chain of Custody, Chain of Identity, and Lonza’s proprietary solutions including MODA-ES™.
     
  • Lonza's global cell & gene therapy manufacturing network provides worldwide access to cell and gene therapeutic technologies for customers to serve patients globally
     
  • Vineti’s supply chain orchestration (SCO) platform enables real-time end-to-end connection between manufacturing and points of care while optimizing manufacturing capacity management.

Quote from Alberto Santagostino, SVP Head of Cell & Gene Technologies, Lonza Pharma & Biotech:

“Our customers and their patients are at the heart of this partnership. With Vineti's integrated software platforms, specifically designed to support cell and gene therapies, we have a highly scalable solution both geographically and in volume of output that takes us right where we want to be. As our customers move towards commercialization with increasing patient population sizes, they need reliable, fast and efficient technologies and infrastructures to handle seamlessly the collection, process and delivery of their therapies. This is what we aim to achieve with this partnership. Our customers will now also be able to better leverage our global manufacturing network and the centers that will provide their therapy through a well-orchestrated system which encompasses all the modalities of cell and gene therapy. We will continue to challenge ourselves to serve our customers better in this growing field, now and in the future.”

Quote from Amy DuRoss, CEO and Co-founder, Vineti:

“We’re very honored to have been selected as Lonza’s preferred supply chain orchestration partner,” said Amy DuRoss, CEO and Co-founder of Vineti. “Vineti and Lonza have a shared vision to grow, scale, and standardize the production and operations of cell and gene therapy worldwide. We’re very excited to serve biopharmaceutical partners together and to help open up patient access to these therapies more than ever before.”


Basel, Switzerland and San Francisco, CA, USA, 17 July 2019 – Lonza and Vineti announced today their partnership in the cell and gene therapy field and across Lonza's 'vein-to-vein' delivery network. As a part of this commitment, both Lonza and Vineti become preferred partners, respectively for patient tissue tracking and for contract development and manufacturing services in cell and gene therapy.

The unique partnership comprises a fully integrated offering including logistics, scheduling, distribution, Chain of Condition, Chain of Custody, Chain of Identity, and Lonza’s proprietary solutions such as MODA-ES™. With the goal of seamless service for Lonza's customers and their patients, Lonza and its partners will work to remove the supply chain hurdles faced by developers of personalized therapeutics - including autologous therapies, matched-allogeneic therapies, and personalized cancer vaccines - as they prepare for the commercial launch of their therapies.

The Vineti supply chain orchestration (SCO) platform, the only independent solution known today to serve commercial cell & gene therapy products, will help Lonza’s customers to keep a real-time end-to-end connection between Lonza and the points of care that prescribe their therapies. Together, the Lonza-Vineti solution will seek to provide biopharmaceutical developers with a pre-integrated SCO and manufacturing system that will offer digital, optimized end-to-end traceability and control. The partnership aims to establish faster, simpler operations and scale for cell and gene therapies, and to reduce the time that biopharmaceutical developers need to spend evaluating, implementing, and validating different systems. The partnership will also be working to provide this integrated system worldwide, using Lonza’s global manufacturing presence and Vineti’s ever-expanding network of leading medical centers. The Lonza-Vineti integrated solution will include Lonza’s proprietary solutions such as MODA-ES™, a next-generation electronic batch record execution solution that offers specific functionalities for cell and gene therapies manufacturing.

Browse All News
Bg